Key result
This review outlines the pathogenesis, diagnosis, and treatment strategies for diastolic dysfunction and heart failure with preserved ejection fraction in patients with end-stage kidney disease.
This review summarizes the pathogenesis, diagnosis, and treatment of diastolic dysfunction and HFpEF in patients with end-stage kidney disease.
Diastolic dysfunction is frequently observed in end-stage kidney disease (ESKD), and ESKD patients have many risk factors for heart failure (HF), including hypertension, diabetes, and coronary artery disease. Diastolic HF, also called HF with preserved ejection fraction, refers to a clinical syndrome in which patients have symptoms and signs of HF, normal or near normal left ventricular (LV) systolic function, and evidence of diastolic dysfunction manifested by abnormal LV filling and elevated filling pressure. Recent reports suggest that HF with preserved ejection fraction is more common in hemodialysis patients than HF with low ejection fraction. Diastolic HF in ESKD patients is a strong predictor of death. In this article, we review the information available in the literature on the pathogenesis, diagnosis, and potential treatment strategies of diastolic dysfunction or diastolic HF based on evidence obtained in the general population that is potentially applicable to ESKD patients.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2015) conducted a review in End-stage kidney disease and diastolic dysfunction. This review outlines the pathogenesis, diagnosis, and treatment strategies for diastolic dysfunction and heart failure with preserved ejection fraction in patients with end-stage kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: